Breast cancer biomarkers, and a new clinical category for HER2 expression

$ 11.99

4.7 (549) In stock

Recent advances in treating breast cancer are reaching back to the past to the first known biomarker, human epidermal growth factor, to determine its value in treating patients

Table 2 from Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes

Prognostic and predictive biomarkers in breast cancer: Past, present and future.

Metastatic Breast Cancer Enters a New Era of HER2 Classification

How digital biomarker assays can harness the power of deep learning from clinical trials to the clinic

Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer - Computational and Structural Biotechnology Journal

Interobserver Variation in the Assessment of Immunohistochemistry Expression Levels in HER2-Negative Breast Cancer: Can We Improve the Identification of Low Levels of HER2 Expression by Adjusting the Criteria? An International Interobserver Study

Scoring HER2 expression across the full spectrum - CAP TODAY

Imaging of HER2 detected receptor expression positive breast cancer: from detection to interpretation, Egyptian Journal of Radiology and Nuclear Medicine

Frontiers HER2 Low, Ultra-low, and Novel Complementary Biomarkers: Expanding the Spectrum of HER2 Positivity in Breast Cancer

HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles